NAINR. 2013;13(4):189-195.

The chemotherapy regimen itself is agnostic to molecular subtypes of gastric cancer. The authors are to be congratulated for PRODIGE 51-FFCD-GASTFOX, which supports docetaxel as part of the preferred ...

Optune Lua received a CE Mark for treating metastatic NSCLC, used with immune checkpoint inhibitors or docetaxel after progression on a platinum-based regimen. The phase 3 LUNAR trial showed ...

University of Kentucky, Lexington, KY.

Aims: To determine the maximum tolerated dose (MTD), safety and anti-tumor activity of afatinib combined with docetaxel in advanced cancer. Patients & methods: The MTD was determined from dose ...

University of Illinois at Chicago, Chicago, IL.

BCG might be superior to sequential intravesical gemcitabine-docetaxel for reducing the risk of recurrence in patients with high-grade intermediate-risk NMIBC. Given the recent global shortage of ...

Novocure has obtained CE Mark approval for its Optune Lua device to treat adults with metastatic non-small cell lung cancer (NSCLC) simultaneously with immune checkpoint inhibitors or docetaxel. This ...

Risks include infiltration, extravasation, discomfort, phlebitis, bleeding, air embolism, foreign body embolism, infection and interruption to therapy. BD reports 10 serious injuries associated ...

The chemotherapy drug docetaxel has been around for decades, but new research shows if used earlier, it can help men with metastatic prostate cancer live much longer – adding 22 months of life ...

Optune Lua is now approved for use concurrently with immune checkpoint inhibitors or docetaxel in adult patients with metastatic NSCLC who have progressed on or after a platinum-based regimen CE ...

Patients treated with trastuzumab deruxtecan + pertuzumab had a statistically significant and clinically meaningful improvement in PFS compared with standard of care. Topline results were ...